Three newcomers buck the trend, including Kim Jung-soo & Chun In-jang, the couple behind spicy Buldak noodles.

The collective net worth of Korea’s 50 Richest on the 2025 Forbes list fell to US$99 billion from $115 billion last year.

A similar trend was seen on the KOSDAQ, where top-cap stocks such as Alteogen, Ecopro BM, HLB, Ecopro and Rainbow Robotics also slid. As volatility mounted, investors began sharing information about ...

The Kosdaq dipped 0.95 percent, or 6.60 points, to close at 684.85. Drug developer Alteogen slid 2.42 percent to 362,500 won. Ecopro BM, a battery part supplier, lost 4.6 percent to close at ...

AstraZeneca also came together with South Korean company Alteogen to develop the latter’s hyaluronidase utilizing Hybrozyme platform technology ALT-B4. The platform allows for the subcutaneous ...

Here we highlight a subset of our preferred stocks from the screener. Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AstraZeneca will acquire the worldwide rights to use ALT-B4 to develop and commercialize formulations of several undisclosed cancer drugs, whereas Alteogen will be responsible for the clinical and ...

The biotech linked BNT327 to a median overall survival (OS) of 16.8 months in a Chinese phase 2 trial, suggesting the drug candidate could set a new benchmark in a market served by AstraZeneca and ...

The subcutaneous version is also planned for European markets by 2026. Merck and its partner, Alteogen, are prepared for potential patent disputes yet remain committed to advancing Keytruda's new ...

Previous articleStockWatch: Will Trump Tariffs Return Biopharma Manufacturing to the U.S.?